SCHEMBL7805307

SCHEMBL7805307

Cc1ccccc1NC(=O)Nc1ccc(NS(=O)(=O)c2cccc(-c3ccc(F)cc3)c2)c(C)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDX3X O00571 2/20 0.50
IDH1 O75874 1/20 0.49
KMT2A Q03164 5/20 0.49
MAPT P10636 4/20 0.49
MEN1 O00255 4/20 0.49
MAPK1 P28482 3/20 0.49
LMNA P02545 3/20 0.49
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
CA2 P00918 2/20 0.48
CA9 Q16790 2/20 0.48
NPSR1 Q6W5P4 3/20 0.48
STING1 Q86WV6 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HPGD P15428 2/20 0.47
TSHR P16473 2/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11956180 0.93 DDX3X (0.51) DDX3XIDH1KMT2AMAPTMEN1
SCHEMBL7798880 0.93 MAPT (0.55) IDH1KMT2AMAPTMEN1MAPK1
SCHEMBL7805415 0.91 GHSR (0.54) DDX3XIDH1KMT2AMAPTMEN1
SCHEMBL7811207 0.87 LMNA (0.55) IDH1KMT2AMAPTMEN1MAPK1
SCHEMBL7806992 0.81 CNR1 (0.58) KMT2AMAPTMEN1MAPK1LMNA
SCHEMBL7803343 0.80 MAPT (0.69) KMT2AMAPTMEN1MAPK1LMNA
SCHEMBL7805405 0.80 ITGB3 (0.51) IDH1KMT2AMAPTLMNASTING1
SCHEMBL7805558 0.80 IDH2 (0.61) KMT2AMAPTMEN1MAPK1LMNA
SCHEMBL7805723 0.79 CNR1 (0.58) KMT2AMAPTMEN1MAPK1LMNA
SCHEMBL7797547 0.79 KMT2A (0.64) IDH1KMT2AMAPTMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
WO-2010146236-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORP. (FI) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES ITGA1, ITGB1, ITGA2B DDX3X 3725/4885IDH1 1543/4885KMT2A 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.